NCT02765399 is a Phase 4 clinical trial of Liraglutide in Type 2 Diabetes, sponsored by Helsinki University Central Hospital.

Who is sponsoring NCT02765399?

NCT02765399 is sponsored by Helsinki University Central Hospital.

What drugs are being tested in NCT02765399?

Interventions in NCT02765399: Liraglutide, Placebo.

What condition does NCT02765399 study?

NCT02765399 studies Type 2 Diabetes.

Is NCT02765399 still recruiting?

NCT02765399 is currently completed. Last updated 12 April 2022.

Are results published for NCT02765399?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-04-12 · How we verify

NCT02765399

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis

Completed Phase 4 Results posted Last updated 12 April 2022

What this trial tests

Phase 4 trial testing Liraglutide in Type 2 Diabetes in 23 participants. Completed in 28 February 2019.

Timeline

1 February 2015

Primary endpoint
28 February 2019

28 February 2019

Quick facts

Lead sponsor	Helsinki University Central Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	23
Start date	1 February 2015
Primary completion	28 February 2019
Estimated completion	28 February 2019
Sites	1 location across Finland

Drugs / interventions tested

Liraglutide (liraglutide) — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Helsinki University Central Hospital

Who can join

Adults 30 to 75, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Liver Fat Content Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): mean liver fat content was measured by magnetic resonance imaging. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	14.8	± 7.4
Placebo	16.1	± 9.3

16 weeks

Group	Value	95% CI
Liraglutide	10.7	± 6.3
Placebo	13.9	± 9.7

Plasma Triglyceride (TG) Area Under Curve (AUC) Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): postprandial plasma TG summary measured using the trapezoidal rule and expressed as AUC (at fasting and at 0.5, 1, 2, 3, 4, 6 and 8 hours) after oral fat tolerance test. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	22.0	± 7.4
Placebo	17.5	± 4.8

16 weeks

Group	Value	95% CI
Liraglutide	17.1	± 5.0
Placebo	19.0	± 6.2

Body Weight Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): Change in body weight. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	98.6	± 11.0
Placebo	92.0	± 7.4

16 weeks

Group	Value	95% CI
Liraglutide	96.1	± 11.2
Placebo	89.8	± 6.3

Change in HbA1c Level Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): Change in B -Hemoglobiini-A1c level in plasma. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	7.0	± 1.0
Placebo	6.3	± 0.3

16 weeks

Group	Value	95% CI
Liraglutide	6.4	± 0.7
Placebo	6.4	± 0.5

Change in fP-glucose Level Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): concentration of fasting plasma glucose measured using the hexokinase method. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	8.3	± 2.4
Placebo	6.5	± 0.8

16 weeks

Group	Value	95% CI
Liraglutide	6.4	± 1.2
Placebo	6.4	± 0.9

Change in Insulin Level Primary · Baseline and after16 weeks

Before vs after intervention (Liraglutide or placebo): Concentration of insulin level in plasma measured using electrochemiluminescence. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	13.9	± 4.8
Placebo	13.8	± 6.9

16 weeks

Group	Value	95% CI
Liraglutide	14.5	± 4.9
Placebo	14.1	± 5.5

Change in Matsuda Index Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): Matsuda index was calculated for assessment of insulin sensitivity in plasma at time points 0, 30, 60 and 120 minutes using formula 10,000/square root of \[fasting glucose x fasting insulin\] x \[mean glucose x mean insulin during oral glucose tolerance test\]. The Matsuda index is considered to be the gold standard to determine insulin sensitivity without glucose clamp studies (Matsuda M, DeFronzo RA. Diabetes Care. 22:1462-70). Subjects who don't have insulin resistance have values of Matsuda Index of 2.5 or higher (Kerman WN et al. Stro

Baseline

Group	Value	95% CI
Liraglutide	2.5	± 1.0
Placebo	3.1	± 1.7

16 weeks

Group	Value	95% CI
Liraglutide	3.5	± 1.8
Placebo	3.1	± 1.3

Change in VAT Area Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): visceral adipose tissue area measured by magnetic resonance imaging (MRI). Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	3403	± 941
Placebo	2710	± 836

16 weeks

Group	Value	95% CI
Liraglutide	3185	± 1014
Placebo	2600	± 825

Change in SAT Area Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): subcutaneous adipose tissue area measured by magnetic resonance imaging (MRI). Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	4043	± 1129
Placebo	5400	± 1598

16 weeks

Group	Value	95% CI
Liraglutide	3792	± 1185
Placebo	5161	± 1653

Change in ApoCIII Level Primary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): apolipoprotein CIII concentration in plasma measured by using turbidimetric immunoassay. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	12.0	± 4.4
Placebo	9.7	± 2.8

16 weeks

Group	Value	95% CI
Liraglutide	9.9	± 3.7
Placebo	8.6	± 1.8

Change in Hepatic de Novo Lipogenesis Secondary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): Hepatic DNL is calculated from enrichment of deuterated water ingested during the kinetic study at specified time points (0, 4 and 8 hrs.). Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	15.4	± 7.4
Placebo	12.6	± 7.5

16 weeks

Group	Value	95% CI
Liraglutide	19.1	± 13.1
Placebo	13.8	± 11.2

Change in Systolic RR Secondary · Baseline and after 16 weeks

Before vs after intervention (Liraglutide or placebo): systolic blood pressure measurements. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019.

Baseline

Group	Value	95% CI
Liraglutide	135	± 14
Placebo	145	± 10

16 weeks

Group	Value	95% CI
Liraglutide	139	± 11
Placebo	137	± 11

Adverse events — posted to ClinicalTrials.gov

Time frame: During 16 weeks of Liraglutide therapy. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Liraglutide

Serious: 0/16 (0%)

Deaths: 0/16

Placebo

Serious: 0/7 (0%)

Deaths: 0/7

Other adverse events (1 terms — click to expand)

Reaction	System	Liraglutide	Placebo
Nausea	General disorders	—	—

Data from ClinicalTrials.gov NCT02765399 adverse events section.

Sponsor's own description

This study aims to evaluate the mechanisms underlying the effect of incretin therapy on lipoprotein metabolism in subjects with type 2 diabetes and to study the effect of liraglutide on hepatic de novo lipogenesis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
Matikainen N, Söderlund S, Björnson E, Pietiläinen K, et al · · 2019 · cited 91× · PMID 30073766 · DOI 10.1111/dom.13487

Verify or expand the search:

Other trials of Liraglutide

Trials testing the same drug.

NCT07225816 — Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in · Phase 1 · recruiting
NCT06818292 — Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists · NA · completed
NCT06283641 — Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. · completed
NCT06501326 — Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease · Phase 4 · unknown
NCT05756764 — Anti-obesity Pharmacotherapy and Inflammation · active not recruiting

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Helsinki University Central Hospital trials

Trials by the same sponsor.

NCT07423637 — The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectivene · NA · not yet recruiting
NCT07462559 — KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study · Phase 1 · not yet recruiting
NCT07458984 — FMT Capsules for rCDI · Phase 3 · not yet recruiting
NCT07001423 — ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly · NA · recruiting
NCT07155629 — Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02765399 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Helsinki University Central Hospital
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02765399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02765399

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of Liraglutide

Other recruiting trials for Type 2 Diabetes

Other Helsinki University Central Hospital trials

Verify against primary sources